Mainz Biomed Announces Annual General Meeting

BERKELEY, US – MAINZ, Germany – May 23, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that its annual general meeting (the “AGM”) will be held at the offices of CMS Netherlands, Atrium, Parnassusweg 737, 1077 DG Amsterdam, the […]

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)

Dante Labs is a Global Leader in Genomics and Precision Medicine Mainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer BERKELEY, Calif. and MAINZ, Germany and New York, MAY 19, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early […]

Mainz Biomed to Host Key Opinion Leader Event at DDW 2022

Digestive Disease Week is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery BERKELEY, US – MAINZ, Germany – MAY 9th, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced […]

Mainz Biomed Provides Product Development Update on PancAlert

Novel Screening Test for Pancreatic Cancer Funded by the German Government Achieved Key Project Milestones; Next Phase of Development Launched BERKELEY, Calif. and MAINZ, Germany, May 5, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that PancAlert, its […]

Mainz Biomed Appoints Darin Leigh as Chief Commercial Officer

Former Abbott and Luminex executive with over 30 years of In Vitro Diagnostic (IVD) and life science research experience appointed to execute the international commercialization of ColoAlert and drive the development of the Mainz Biomed’s portfolio of cancer detection products BERKELEY, US – MAINZ, Germany – APRIL 26th, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz […]

Mainz Biomed Announces First Quarter 2022 Results

BERKELEY, US – MAINZ, Germany – April 12, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today operational results for the first quarter ended March 31, 2022. Key Highlights Continued to ramp up EU commercial activities for ColoAlert, the […]

Mainz Biomed to Ring Nasdaq Stock Market Closing Bell

BERKELEY, Calif. and MAINZ, Germany, March 21, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that Guido Baechler, Chief Executive Officer, will ring the closing bell at Nasdaq MarketSite in New York’s Times Square today, Monday, March 21st, 2022 […]

Mainz Biomed Appoints Key Clinical Trial Partners for ColoFuture Study

Cutting Edge IVD Developer Sentinel Chosen to Provide Automated FIT Analysis System Leading Clinical Research Organization Alcedis Selected to Manage the Study ColoFuture on track to complete enrollment in 2H 2022  BERKELEY, Calif. and MAINZ, Germany, March 17, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing […]